The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
You are here Home Guidance and resources Sponsors Kadmon Oceania Pty Ltd Regulatory activities for this sponsor. Listen Print Share Loading... Type Designation or determination (2) (-) Designation or determination (2) Prescription medicine registration (1) (-) Prescription medicine registration (1) Australian Public Assessment Report (AusPAR) (1) Australian Public Assessment Report (AusPAR) (1) Prescription medicine decision summary (1) Prescription medicine decision summary (1) Date 2021 (1) 2021 (1) 2020 (2) 2020 (2) Search Filters applied:Designation or determinationPrescription medicine registrationClear all Sponsor content3 result(s) found, displaying 1 to 3 RHOLISTIQ (Kadmon Oceania Pty Ltd) 11 November 2021 Prescription medicine registration Active ingredients: belumosudil mesilate. Notice for belumosudil (Kadmon Oceania Pty Ltd) 15 September 2020 Designation or determination Priority review Notice for belumosudil (Kadmon Oceania Pty Ltd) 4 September 2020 Designation or determination Orphan drug
RHOLISTIQ (Kadmon Oceania Pty Ltd) 11 November 2021 Prescription medicine registration Active ingredients: belumosudil mesilate.
Notice for belumosudil (Kadmon Oceania Pty Ltd) 15 September 2020 Designation or determination Priority review
Notice for belumosudil (Kadmon Oceania Pty Ltd) 4 September 2020 Designation or determination Orphan drug